Product Information
AMPHETAMINE ER 6.3 MG ODT is a generic product labeled by Neos Therapeutics Brands, LLC, priced at $16.0732 per EA under NDC 62542001030. Its NADAC has been published 33 times since Feb 18, 2026.
FDA first approved this application on Jan 27, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
6.3 mg/1
Manufacturer
Neos Therapeutics Brands, LLCNDC
62542001030
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMPHETAMINEApproval Type
Authorized Generic (NDA)
FDA Application
NDA204326FDA Approved
1/27/2016
TE Code
AB
On Market Since
9/1/2025
Pharmacological Classes
Price Statistics
The NADAC for AMPHETAMINE ER 6.3 MG ODT has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $16.0732 per EA |
|---|---|
| All-time high | $16.4710 (Apr 15, 2026) |
| All-time low | $16.0732 (Sep 23, 2026) |
| 52-week high | $16.4710 |
| 52-week low | $16.0732 |
| Median price | $16.3419 |
| Average price | $16.3071 |
| Largest weekly change | -1.0% (Sep 23, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Amphetamine Extended-Release market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Neos Therapeutics Brands, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amphetamine Extended-Release market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMPHETAMINE ER 6.3 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for AMPHETAMINE ER 6.3 MG ODT, manufactured by Neos Therapeutics Brands, LLC, is $16.0732 per EA (NDC 62542001030), effective Sep 30, 2026.
How has the price of AMPHETAMINE ER 6.3 MG ODT changed over time?
Over the history we have for it, the NADAC for AMPHETAMINE ER 6.3 MG ODT has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for AMPHETAMINE ER 6.3 MG ODT?
Since Feb 18, 2026, the NADAC for AMPHETAMINE ER 6.3 MG ODT has ranged from a low of $16.0732 (Sep 23, 2026) to a high of $16.4710 (Apr 15, 2026), with a median of $16.3419 per EA.
Are there cheaper alternatives to AMPHETAMINE ER 6.3 MG ODT?
No other NADAC-published product currently shares the active ingredient and strength of AMPHETAMINE ER 6.3 MG ODT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AMPHETAMINE ER 6.3 MG ODT?
AMPHETAMINE ER 6.3 MG ODT (NDC 62542001030) is labeled by Neos Therapeutics Brands, LLC, and CMS classifies it as a generic product.